Clinical trial · Interventional
Contrast-enhanced CBCT With C-arm HyperSight Technology
Contrast-enhanced CBCT With C-arm HyperSight Technology: A Feasibility Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a single-arm prospective, feasibility study evaluating the intravenous contrast-enhanced cone beam computed tomography (IV CBCT) for image guidance during radiotherapy. Patients treated with SFRT will receive IV-contrast enhanced CT and fMRI before treatment for simulation purposes. Additionally, patients will receive mpMRI just before and IV-contrast enhanced CBCT during their second and last fraction of RT, in addition to the standard of care CBCT that is acquired for daily image-guided patient positioning. Patients will undergo both IV-contrast enhanced CBCT and treatment on the TrueBeam with HyperSight imaging capability. We hypothesize IV contrast enhanced CBCT is feasible, well-tolerated by patients and improves the visibility of the target.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Intravenous contrast-enhanced cone beam computed tomography | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- IV CBCT
- interventionNames
- Diagnostic Test: Intravenous contrast-enhanced cone beam computed tomography
Primary outcomes (1)
- measure
- Feasibility of IV-contrast enhanced CBCT during image-guided radiotherapy
- timeFrame
- 18 Months
- description
- Feasibility of IV-contrast enhanced CBCT in visualizing tumors, vascular structures and tumour micro-environment changes during image-guided radiotherapy. The contrast-to-noise ratio, measuring the ability of an imaging modality to differentiate between various contrasts against the background noise, will be calculated and compared between CT and CBCT, and between with and without contrast acquisition.
Secondary outcomes (3)
- measure
- Feasibility of dynamic-contrast-enhanced (DCE) imaging
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Primary biopsy-proven cancer * Planning to undergo spatially fractionated radiation therapy * Able to provide informed consent * Willingness to participate in follow-up * ECOG less than or equal to 3 * Normal creatinine (below 109mmol/L), normal eGF Exclusion Criteria: * Unable to understand/provide consent * History of allergic reaction to iodinated IV contrast dye (allergy to MR contrast is not an exclusion criteria) * Known renal disease * Single kidney * Kidney transplant * Dialysis * Contraindication to MRI
References
Publications (0)
Data not yet available